Home Crystal structure of N,N-diethyl-5-bromo-3,4-dihydro-2,4-dioxopyrimidine-1(2H)-carboxamide, C9H12BrN3O3
Article Open Access

Crystal structure of N,N-diethyl-5-bromo-3,4-dihydro-2,4-dioxopyrimidine-1(2H)-carboxamide, C9H12BrN3O3

  • Guang-Hui Wu , Xian-Bo Shi , Yu-Feng Lian , Hua-Bin Xiang and Jing Xiong EMAIL logo
Published/Copyright: October 29, 2016

Abstract

C9H12BrN3O3, monoclinic, P21/c, a = 12.0359(15) Å, b = 5.4815(6) Å, c = 20.1931(18) Å, β = 120.780(5)°, V = 1144.6(2) Å3, Z = 4, Rgt(F) = 0.0234, wRref(F2) = 0.0984, T = 298(2) K.

CCDC no.:: 849470

The crystal structure is shown in the figure. Tables 1 and 2 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.

Table 1

Data collection and handling.

Crystal:Colourless blocks
Size:0.23 × 0.21 × 0.15 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:35.9 cm−1
Diffractometer, scan mode:Bruker SMART, φ and ω
2θmax, completeness:51°, >99%
N(hkl)measured, N(hkl)unique, Rint:8372, 2110, 0.016
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 1966
N(param)refined:147
Programs:SHELX [12], Bruker programs [13]
Table 2

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
Br10.71787(2)1.20095(5)0.488722(13)0.04568(15)
O10.71650(19)0.5267(3)0.71596(10)0.0504(5)
O20.54412(17)0.7537(3)0.46557(10)0.0412(4)
O30.99192(14)0.9442(3)0.79331(10)0.0447(4)
N10.78465(17)0.8869(3)0.69097(10)0.0315(4)
N20.63237(18)0.6462(4)0.59107(11)0.0361(4)
H20.58250.52060.57620.043*
N30.82766(16)0.9831(4)0.81657(10)0.0336(4)
C10.7116(2)0.6737(4)0.67001(13)0.0349(5)
C20.6233(2)0.7938(4)0.53359(13)0.0321(5)
C30.7147(2)0.9948(4)0.56208(12)0.0311(4)
C40.79035(19)1.0350(4)0.63794(12)0.0311(4)
H40.84781.16560.65500.037*
C50.87808(19)0.9373(4)0.77274(12)0.0317(4)
C60.9208(2)1.0503(5)0.89705(13)0.0468(6)
H6A0.99810.95140.91600.056*
H6B0.88331.01600.92860.056*
C70.9573(3)1.3155(6)0.9047(2)0.0650(9)
H7A0.88351.41400.89300.097*
H7B0.98621.35400.86960.097*
H7C1.02571.34790.95650.097*
C80.6898(2)1.0229(5)0.79035(14)0.0401(5)
H8A0.63961.01220.73460.048*
H8B0.67921.18630.80480.048*
C90.6369(3)0.8402(6)0.8240(2)0.0600(8)
H9A0.68580.85040.87920.090*
H9B0.64390.67850.80820.090*
H9C0.54780.87640.80580.090*

Source of material

5-Bromouracil (0.29 g, 1 mmol), bis(trichloromethyl) carbonate (0.118 g, 0.4 mmol), anhydrous dichloromethane (DCM) (5 mL) were added into a flask. Pyridine (2 mL) was added dropwise to the mixture and stirred at 273 K for 30 min. Triethylamine (0.222 g, 2.2 mmol) was then added to the mixture and stirred for 6 hours at room temperature until the reaction finished as monitored by thin-layer chromatography (TLC). A solid was obtained after removal of DCM and pyridine and purified by silica gel column chromatography. The purified product was dissolved in ethanol forming crystals after 10 days.

Experimental details

H atoms were positioned geometrically and allowed to ride on their parent atoms using the corresponding AFIX options of the SHELX system.

Discussion

The 5-halouracils and their derivatives have demostrated antitumor and antiviral properties [1; 2; 3; 4]. For example, 5-fluorouracil is known as one of the anticancer agents used clinically for the treatment of stomach, colorectal, and neck cancers [5, 6]. Some 5-chlorouracil derivatives have been reported as thymidine phosphorylase inhibitors [7, 8]. And some of 5-bromouracil derivatives have been studied to treat inflammatory tissue [9]. We herein describe the synthesis and X-ray structure determination of a 5-bromouracil derivative, namely N,N-diethyl-5-bromo-3,4-dihydro-2,4-dioxopyrimidine-1(2H)-carboxamide.

In the title molecule bond lengths in the pyrimidine ring are within the range reported for similar compounds [10]. And the atoms (C1, C2, C3, C4, N1 and N2) in the uracil ring are slightly puckered, with an r.m.s. deviation of 0.0335 Å. The effects of conjugation in the heterocyclic ring are evident for the bond length to N1, N2, which are 1.373(3) Å and 1.391(3) Å for N1—C4 and N1—C1, 1.373(3) Å and 1.385(3) Å for N2—C2 and N2—C1, respectively. The values are signficantly shorter than the N—C single bond of 1.48 Å [11]. Consequently, the C2—C3 bond lengths 1.452(3) Å is shorter than a C—C single bond. Molecules interact mainly through intermolecular hydrogen bonds formed by the NH group and one of the C=O groups: N2—H2⋯O2i (symmetry code i: −x + 1, −y + 1, −z + 1) hydrogen bond.

Acknowledgements

We acknowledge financial support by Wenzhou Technology Project Foundation (No. 2016G0036).

References

1 Kratz, F.; Müller, L. A.; Ryppa, C.; Warnecke, A.: Prodrug strategies in anticancer chemotherapy. ChemMedChem 3 (2008) 20–53.10.1002/cmdc.200700159Search in Google Scholar PubMed

2 Novikov, M. S.; Buckheit Jr., R. W.; Temburnikar, K.; Khandazhinskaya, A. L.; Ivanod, A. V.; Seley-Radtke, K. L.: 1-Benzyl derivatives of 5-(arylamino)uracils as anti-HIV-1 and anti-EBV agents. Bioorg. Med. Chem. 18 (2010) 8310–8314.10.1016/j.bmc.2010.09.070Search in Google Scholar PubMed

3 Wang, X. W.; Zhang, J. F.; Huang, Y.; Wang, R. P.; Zhang, L.; Qiao, K.; Li, L.; Liu, C.; Ouyang, Y. B.; Xu, W. S.; Zhang, Z. L.; Zhang, L. R.; Shao, Y. M.; Jiang, S. B.; Ma, L. Y.; Liu, J. Y.: Design, synthesis, and biological evalution of 1-[(2-benzyloxy/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile. J. Med. Chem. 55 (2012) 2242–2250.10.1021/jm201506eSearch in Google Scholar PubMed PubMed Central

4 Hitchcock, D. S.; Fedorov, A. A.; Fedorov, E. A.; Almo, S. C.; Raushel, F. M.: Discovery of a bacterial 5-methylcytosine deaminase. Biochemistry 53 (2014) 7426–7435.10.1021/bi5012767Search in Google Scholar PubMed PubMed Central

5 Ahmad, M. Z.; Akhter, S.; Anwar, M.; Ahmad, F. J.: Assam bora rice starch based biocompatible mucoadhesive microsphere for targeted delivery of 5-fluorouracil in colorectal cancer. Mol. Pharmaceutics 9 (2012) 2986–2994.10.1021/mp300289ySearch in Google Scholar PubMed

6 Cho, J. H.; Amblard, F.; Coats, S. J.; Schinazi, R. F.: Synthesis of cyclopentanyl carbocyclic 5-fluorcytosine ((-)-5-florocarbodine) using a facially selective hydrogenation approach. J. Org. Chem. 78 (2013) 723–727.10.1021/jo302038dSearch in Google Scholar PubMed PubMed Central

7 Sun, L. Y.; Li, J. R.; Bera, H.; Dolzhenko, A. V.; Chiu, G. N. C.; Chiu, W. K.: Fragment-based approach to the design of 5-chlorouracil-linked-pyrazolo[1,5-a][1, 3, 5]triazines as thymidine phosphorylase inhibitors. Eur. J. Med. Chem. 70 (2013) 400–410.10.1016/j.ejmech.2013.10.022Search in Google Scholar PubMed

8 Lu, H. Y.; Klein, R. S.; Schwartz, E. L.: Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap. Clin. Cancer Res. 15 (2009) 5136–5144.10.1158/1078-0432.CCR-08-3203Search in Google Scholar PubMed PubMed Central

9 Yang, Z. B.; Rodgers, M. T.: Influence of halogenation on the properties of uracil and its noncovalent interactions with alkali metal ions. Threshold collision-induced dissociation and theoretical studies. J. Am. Chem. Soc. 126 (2004) 16217–16226.10.1021/ja045375pSearch in Google Scholar PubMed

10 Yao, T.; Yi, J. C.; Zhou, S. G.; Xiong, J.: Synthesis, structural, and UV studies of two uraicl derivatives, methyl 3-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate and methyl 3-(5-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate. J. Chem. Crystallogr. 43 (2013) 383–389.10.1007/s10870-013-0432-zSearch in Google Scholar

11 Chaudhuri, G.; Helliwell, M.; Kundu, N. G.: (Z)-7-chloro-3-[(3-chlorophenyl)methylidene]-4-p-tosyl-3,4-dihydro-2H-1,4-benzoxazine. Acta Crystallogr. C57 (2001) 740–741.10.1107/S0108270101004036Search in Google Scholar

12 Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Search in Google Scholar PubMed

13 Bruker. APEX2, SAINT and SADABS. Brucker AXS Inc., Madison, Wisconsin, USA, (2002).Search in Google Scholar

Received: 2016-5-26
Accepted: 2016-10-7
Published Online: 2016-10-29
Published in Print: 2017-1-1

©2016 Guang-Hui Wu et al., published by De Gruyter.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Articles in the same Issue

  1. Cover and Frontmatter
  2. Editorial
  3. Twenty years of crystal structure publication and the road ahead
  4. Crystal Structures
  5. Crystal structure of poly-[triaqua-(μ4-5′-carboxy-[1,1′-biphenyl]-2,3,3′-tricarboxylate-κ6O1,O2:O3,O4:O5:O6)praseodymium(III), C16H13O11Pr
  6. Crystal structure of (R)-1-(2,3-dihydro-1H-pyrrolizin-5-yl)-2,3-dihydroxypropan-1-one, C10H13NO3
  7. Crystal structure of (E)-4-nitro-2-((2-phenoxyphenylimino)methyl)phenol, C19H14N2O4
  8. Crystal structure of 3,3′-di(furan-2-yl)-5,5′-bi-1,2,4-triazine
  9. Crystal structure of 11-(p-coumaroyloxy)-tremetone, C22H20O5
  10. The crystal structure of 1,3-bis(2,6-diiso-propylphenyl)imidazol-2-ylidene)-dibromido-(1-methyl-1H-imidazole-κ1N)palladium(II) – ethyl acetate – water (1/1/1), C31H42Br2N4Pd
  11. Crystal structure of 2-((3-(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1H-indene-1,3(2H)-dione, C28H19N5O2
  12. Crystal structure of 2-(5-(4-fluorophenyl)-3-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)-4-(5-methyl-1-p-tolyl-1H-1,2,3-triazol-4-yl)thiazole, C29H25FN6S
  13. Crystal structure of poly-[aqua-(μ7-benzene-1,3,5-tricarboxylato)-(μ3-1,2,4-triazol-1-ido)dicobalt(II)], C11H7Co2N3O7
  14. Crystal constructure of 16(S)-methyl-6α-carboxy-1, 15-dioxo-6, 7-seco-ent-kaur-2-en-7, 20-olide, C20H24O6
  15. Crystal structure of 1-(benzo[d]thiazol-2-yl)-3-phenylthiourea, C14H11N3S2
  16. Crystal structure of 3-(2-bromophenyl)-1,1-dimethylthiourea, C9H11BrN2S
  17. Crystal structure of 1-(adamantan-1-yl)-3-(3-chlorophenyl)thiourea, C17H21ClN2S
  18. Crystal structure of 3-(adamantan-1-yl)-1-(4-bromophenyl)urea, C17H21BrN2O
  19. Crystal structure of (Z)-Ethyl 2-cyano-2-(3-phenylthiazolidin-2-ylidene) acetate, C14H14N2O2S
  20. Crystal structure of methyl 2b-ethyl-1a,2a,2b,2b1,3,5,10,11-octahydro-1H-oxireno[2′,3′:6,7]indolizino[8,1-cd]carbazole-4-carboxylate, C21H24N2O3
  21. Crystal structure of 2-amino-5-oxo-4-(3,4,5-trimethoxy-phenyl)-4,5,6,7-tetrahydro-cyclopenta[b]pyran-3-carbonitrile, C18H18N2O5
  22. Crystal structure of 1,2,3-trimethyl-2,3-dihydro-1H-perimidine, C14H16N2
  23. Crystal structure of bis(2,6-dihydroxymethyl)pyridine-κ3N,O,O′)-bis(μ2-6-chloropyridin-2-olato-κ3N,O:O)-bis(6-chloropyridin-2-olato-κO)-bis(nitrato-κ2O,O′)digadolinium(III), C34H30Cl4Gd2N8O14
  24. Crystal structure of 8-isopropyl-8-aza-bicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate, C19H27NO3
  25. Crystal structure of 1-methyl-3-[((naphthalen-2-ylsulfonyl)oxy)imino]indolin-2-one, C19H14N2O4S
  26. Crystal structure (7,8-bis(diisopropylphosphino)-7,8-dicarba-nido-undecaborane-κ2P,P′)-(benzoato-κ2O,O′)nickel(II), C21H42B9NiO2P2
  27. Crystal structure of methyl-2-methyl-4-(2-oxo-2-phenylethyl)-5-phenyl-1H-pyrrole-3-carboxylate, C21H19NO3
  28. Crystal structure of 2-[(2-oxo-thiazolidine-3-carbonyl)sulfamoyl]-methy-benzoic acid methyl ester, C13H14N2O6S2
  29. Crystal structure of N′-(2-phenylacetyl)thiophene-2-carbohydrazide monohydrate, C13H14N2O3S
  30. Crystal structure of 1,1′-(hexane-1,6-diyl)bis(3-methyl-1H-imidazol-3-ium) bis(hexafluoro phosphate), C14H24F12N4P2
  31. Crystal structure of di-μ-chlorido-bis[1,2-bis(dicyclohexylphosphino)-1,2-dicarba-closo-dodecaborane-κ2P,P′]zinc(II), C52H108B20Cl2P4Zn2
  32. Crystal structure of dibromido-bis[μ-1-[(2-methyl-1H-benzoimidazol-1-yl)methyl]-1H-benzotriazole-κN]mercury(II), C30H26Br2HgN10
  33. Crystal structure of bis(μ-nitrato-κ2O:O)-bis[1,2-bis(diphenylphosphino)-1,2-dicarba-closo-dodecaborane-κ2P,P′]disilver(I) dicloromethane monosolvate, C54H64B20Cl4O6P4Ag2
  34. Crystal structure of dinuclear dichloridobis(dimethylformamide-kO)bis[μ2-3-(2-oxyphenyl)-5-(pyrazin-2-yl)-1,2,4-triazol-1ido-κ4-O,N:N′,N′′(2)]diiron(III) dimethylformamide (1/1), C36H42Cl2Fe2N14O6
  35. Crystal structure of diaqua-dinitrato-κO-bis(4-(1H-pyrazol-3-yl)pyridine-κN)manganese(II), C16H18MnN8O8
  36. Crystal structure of (Z)-6-methoxy-2-(2,2,2-trifluoro-1-hydroxyethylidene)-2,3-dihydro-1H-inden-1-one, C12H6F6O3
  37. Crystal Structure of 4-(2-chloroacetamido)pyridinium chloride monohydrate, C7H10Cl2N2O2
  38. Crystal structure of 2-amino-4-(4-chloro-phenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H13ClN2O2
  39. Crystal structure of (E)-1-(2-(thiophen-2-ylmethylene)hydrazinyl)phthalazine hydrochloride–ethanol (1/1), C15H17ClN4OS
  40. Crystal structure of N,N-diethyl-5-bromo-3,4-dihydro-2,4-dioxopyrimidine-1(2H)-carboxamide, C9H12BrN3O3
  41. Crystal structure of 3-(2-(4-chlorophenyl)-3-hydroxy-3,3-diphenylpropyl)-1,1-dimethylurea, C24H25ClN2O2
  42. Crystal structure of 3-(4-chlorophenyl)-1,1-dimethylthiourea, C9H11ClN2S
  43. Crystal structure of 2-amino-4-(4-bromo-phenyl)-7-methyl-5-oxo-4H,5H-pyrano[4,3-b]pyran-3-carbonitrile, C16H11BrN2O3
  44. Crystal structure of 4-(3,4-dimethyl-phenyl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid ethyl ester, C21H25NO3
  45. Crystal structure of (E)-2-({4-hydroxy-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]phenyl} methylidene)-1-indanone, C23H26N2O3
  46. Crystal structure of tripropylammonium 2′-carboxy-[1,1′-biphenyl]-2-carboxylate – [1,1′-biphenyl]-2,2′-dicarboxylic acid (2/1), C60H72N2O12
  47. Crystal structure of catena-poly-{aqua-[μ2-1,2-bis((1H-imidazol-1-yl)methyl)benzene-κ2N:N′]-[μ2-4,4′-(dimethylsilanediyl)dibenzato-κ3O,O′:O′]nickel(II)}, C30H30N4NiO5Si
  48. The crystal structure of 1-(4-bromophenyl)-2-(4-(4-fluorophenyl)piperazin-1-yl)ethanol, C18H20BrFN2O1
  49. Crystal structure of trimethylammonium 4-((4-carboxyphenyl)sulfonyl)benzoate, C17H19NO6S
  50. Crystal structure of syn-2,4-di-o-tolylpentane-2,4-diol, C19H24O2
  51. Crystal structure of 2-[3,5-bis(trifluoromethyl)benzylsulfanyl]-5-(5-bromothiophen-2-yl)-1,3,4-oxadiazole, C15H7BrF6N2OS2
  52. Crystal structure of (E)-3-((naphthalen-1-ylimino)methyl)-4-nitrophenol, C17H12N2O3
  53. Crystal structure of 2-dichloromethyl-2-p-nitrophenyl-1,3-dioxolane, C10H9Cl2NO4
  54. Crystal structure of (1,4,8,11-tetraazacyclotetradecane)palladium(II) tetracyanopalladate(II), C14H24N8Pd2
  55. Crystal structure of 2-(4-oxo-2-thioxothiazolidin-3-yl)acetic acid monohydrate, C5H7NO4S2
  56. Crystal structure of a P4-bridged (η5-pentamethyl-cyclopentadienyl)(η5-adamantylcyclopentadienyl) titanium(III)complex, C50H66P4Ti2
  57. Crystal structure of cis-bis(2,2′-bipyrimidine-κ2N,N′)bis(thiocyanato-κN)nickel(II), C18H12N10NiS2
  58. Crystal structure of cis-bis(2,2′-bipyridine-κ2N,N′)dibromidomanganese(II), C20H16Br2MnN4
  59. Crystal structure of cis-bis(2,2′-bipyridine-κ2N,N′)bis(thiocyanato-κN)nickel(II), C22H16N6NiS2
  60. Crystal structure of trans-dibromido(1,4,8,11-tetraazacyclotetradecane)nickel(II), C10H24Br2N4Ni
  61. Crystal structure of cis-tetrabromidobis(pyridine-κN)platinum(IV), C10H10Br4N2Pt
  62. Crystal structure of (E)-5-((4-chlorophenyl)diazenyl)-2-(5-(4-fluorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-4-methylthiazole, C23H17ClFN5S2
  63. The crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium tetrachloridocobaltate(II) monohydrate, C10H18Cl4CoN2O
Downloaded on 5.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2016-0169/html
Scroll to top button